ArticleScientific reports2025
Prognostic value of positive lymph node ratio in oral cavity squamous cell carcinoma after neoadjuvant treatment: a retrospective real-world study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to address the prognostic value of positive lymph node ratio for oral cavity squamous cell carcinoma (OCSCC) patients after neoadjuvant treatment, and build a prediction nomogram model. Patients with OCSCC with neoadjuvant treatment were retrieved from the Surveillance, Epidemiology, and End Results database from 2004 to 2021. The primary outcome was overall survival (OS), and the second outcome was disease-specific survival (DSS). Kaplan-Meier and log-rank tests were used to analyze the survival outcomes. Univariable and multivariable analyses were conducted, and then a nomogram was constructed. A total of 419 were included in this study. The optimal cutoff value of the positive lymph node ratio (LNR) was 7.0%. The 5-year OS of patients with low LNR was significantly improved over those with high LNR (p < 0.0001). LNR > 7.0% (HR 50.7, 95% CI 19.7-130.5), and unmarried status (HR 1.33, 95% CI 1.03-1.70) were the independent risk factors for OS (all p < 0.05). LNR > 7.0% (HR 35.8, 95% CI 9.63-132.7), gum primary site (HR 0.330, 95% CI 0.132-0.827), and preoperative chemotherapy and radiotherapy (HR 2.91, 95% CI 1.78-4.73) were the independent risk factors for DSS (all p < 0.05). According to the nomogram, patients were stratified into the high-risk group and the low-risk group for OS and DSS. Patients in the low-risk group were predicted with superior survival (both p < 0.05). The LNR was an independent prognostic factor of the OS and DSS for OCSCC patients after neoadjuvant treatment. The tools may be valuable to guide multidisciplinary teams in making treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.